http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2253307-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cab64dfbe7ad218bda5bdcddbc2bf326
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-205
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23K50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23K50-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23P10-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23K20-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23K20-142
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23K50-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23K50-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-175
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-205
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
filingDate 2007-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4831b2781fe60eaa7e26b93b1530244
publicationDate 2010-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-2253307-A1
titleOfInvention L-Carnitin for supression of crystallisation
abstract The present invention relates to an aqueous composition comprising at least 20% by weight of the magnesium complex compound, magnesium L-aspartate hydrochloride and L-carnitine in a range of 15 to 60% by weight, and their use for producing a Medicament for supporting the metabolism, in particular in the muscle tissue, and the muscle building or their use as dietary supplements or in the veterinary field as animal feed additive, in particular for horses, poultry, pigeons, pigs, cattle, sheep and camels.
priorityDate 2006-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1163904-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0191759-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0402755-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0152647-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0680945-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002132219-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID288
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226411138
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5251
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226411139
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10917
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129629301

Total number of triples: 45.